QUARTERLY STATEMENT

3rd quarter | 1st nine months

26

EVONIK
Leading Beyond Chemistry

A strong third quarter—more precise outlook

3rd quarter

- Continued **good business performance**
- **Sales grew** by 13 percent
- **Adjusted EBITDA** rose 40 percent to €629 million
- **Adjusted EBITDA margin** improved to 16.4 percent

1st nine months

- **Adjusted EBITDA** increased by 14 percent to €1,734 million
- **Net income** declined to €156 million as a result of higher expenses for structural measures
- **Adjusted net income** increased to €784 million
- **Free cash flow** improved significantly to €601 million
- **More precise outlook for 2026: adjusted EBITDA** expected to be in the upper half of the range of €2.0 billion to €2.2 billion

Key figures for the Evonik Group

	3rd quarter		1st nine months	
in € million	2025	**2026**	2025	**2026**
Sales	3,391	3,825	10,666	11,144
Adjusted EBITDA[a]	448	629	1,517	1,734
Adjusted EBITDA margin in %	13.2	16.4	14.2	15.6
Adjusted EBIT[b]	197	389	756	994
Income before financial result and income taxes, continuing operations (EBIT)	-25	-6	510	385
Net income	-106	-53	247	156
Adjusted net income	128	330	563	784
Earnings per share in €	-0.23	-0.11	0.53	0.33
Adjusted earnings per share in €	0.27	0.71	1.21	1.68
Cash flow from operating activities, continuing operations	481	562	831	1,198
Cash outflows for investments in intangible assets, property, plant and equipment	-181	-193	-547	-597
Free cash flow[c]	300	369	284	601
Net financial debt as of September 30	–	–	-3,677	-3,292
No. of employees as of September 30	–	–	31,297	30,319

[a] Earnings before financial result, taxes, depreciation and amortization, after adjustments, continuing operations.
[b] Earnings before financial result and taxes, after adjustments, continuing operations.
[c] Cash flow from operating activities, continuing operations, less cash outflows for investment in intangible assets, property, plant and equipment.

Due to rounding, some figures in this report may not add up exactly to the totals stated.

CONTENTS

INFORMATION ON BUSINESS PERFORMANCE 3

1. **Business conditions and performance** 3
   - 1.1 Business performance 3
   - 1.2 Performance of the segments 5
2. **Financial position** 8
3. **Expected development** 9


SELECTED FINANCIAL INFORMATION 12

- Income statement 12
- Balance sheet 13
- Cash flow statement 14
- Segment report 15


SUPPLEMENTARY INFORMATION 17

- Financial calendar 17
- Credits 17

Sales by segment—1st nine months 2026



Sales by region[a]—1st nine months 2026



[a] By location of customer.

Information on business performance as of September 30, 2026

1. Business conditions and performance


1.1 Business performance

Business performance in Q3 2026

Although economic conditions remained challenging, in the third quarter of 2026, Evonik's performance again significantly exceeded the expectations at the beginning of the year. Following a weak start to the year with low global demand, the outbreak of the war in the Middle East in early March led to higher demand from customers in some businesses and improved selling prices. Even though these exceptional conditions weakened, the Advanced Technologies segment, in particular, remained very successful due to its global position. Overall, adjusted EBITDA improved significantly year-on-year as a result of slightly higher sales volumes and significantly higher prices, as well as the disciplined implementation of efficiency enhancement measures.

In June 2026, Evonik extended the Evonik Tailor Made program and increased its scope. This program includes structural and efficiency measures in both administration and the operating units. During the initial phase from 2024 through 2026, 2,800 jobs will be shed. A further reduction of around 3,200 jobs is planned for the second phase, from 2027 through 2029. The aim of the program is a sustained improvement in the cost structure to strengthen our long-term competitiveness. Expenses of €313 million for structural measures in connection with the extension of the program were recognized in the third quarter of 2026.

Sales by quarter




The Evonik Group's **sales** increased by 13 percent year-on-year to €3,825 million. The organic rise in sales of 12 percent resulted from slightly higher volumes and significantly higher selling prices.

Year-on-year change in sales

in %	1st quarter 2026	2nd quarter 2026	3rd quarter 2026	1st nine months 2026
Volumes	-2	7	2	2
Prices	-1	7	10	5
Organic change in sales	**-3**	**14**	**12**	**7**
Exchange rates	-5	-2	–	-2
Portfolio/other effects	-1	-1	1	-1
Total	**-9**	**11**	**13**	**4**

The 40 percent improvement in **adjusted EBITDA** to €629 million was principally driven by prices. The adjusted EBITDA margin increased to 16.4 percent, compared with 13.2 percent in the prior-year period.

Adjusted EBITDA by quarter



The adjustments of -€395 million contained -€313 million for structural measures, especially expenses for the second phase of the Evonik Tailor Made program. The other special items of -€80 million mainly related to impairment tests pursuant to IAS 36 triggered in the reporting period. These resulted in impairment losses of €264 million, mainly on assets in the Care business in the Custom Solutions segment and the Organics business in the Advanced Technologies segment. By contrast, there were reversals of impairment losses totaling €187 million on the assets of the Animal Nutrition business in the Advanced Technologies segment. The prior-year adjustments of -€222 million mainly comprised impairment losses on the Oxeno assets in the Infrastructure segment. The financial result deteriorated slightly to -€61 million. Income before income taxes, continuing operations improved by 14 percent to -€67 million. Income tax income of €17 million was recorded. Net income increased by €53 million to -€53 million.

Statement of income

	3rd quarter			1st nine months		
in € million	2025	**2026**	Change in %	2025	**2026**	Change in %
Sales	**3,391**	**3,825**	**13**	**10,666**	**11,144**	**4**
Adjusted EBITDA	**448**	**629**	**40**	**1,517**	**1,734**	**14**
Adjusted depreciation, amortization, and impairment losses	-251	-240		-761	-740	
Adjusted EBIT	**197**	**389**	**97**	**756**	**994**	**31**
Adjustments	-222	-395		-246	-609	
thereof structural measures	-31	-313		-36	-365	
thereof acquisitions and divestments	–	-2		-7	-2	
thereof other special items	-191	-80		-203	-242	
Income before financial result and income taxes, continuing operations (EBIT)	**-25**	**-6**	**76**	**510**	**385**	**-25**
Financial result	-52	-61		-126	-147	
Income before income taxes, continuing operations	**-77**	**-67**	**14**	**384**	**238**	**-38**
Income taxes	-25	17		-127	-74	
Income after taxes, continuing operations	**-102**	**-50**	**51**	**257**	**164**	**-36**
Income after taxes, discontinued operations	–	–		–	–	
Income after taxes	**-102**	**-50**	**51**	**257**	**164**	**-36**
thereof income attributable to non-controlling interests	4	3		10	8	
Net income	**-106**	**-53**	**50**	**247**	**156**	**-37**
Earnings per share in €	**-0.23**	**-0.11**		**0.53**	**0.33**	

After adjustment for special items, **adjusted net income** improved by 158 percent to €330 million, and adjusted earnings per share increased from €0.27 to €0.71.

Reconciliation to adjusted net income

	3rd quarter			1st nine months		
in € million	2025	**2026**	Change in %	2025	**2026**	Change in %
Adjusted EBITDA	**448**	**629**	**40**	**1,517**	**1,734**	**14**
Adjusted depreciation, amortization, and impairment losses	-251	-240		-761	-740	
Adjusted EBIT	**197**	**389**	**97**	**756**	**994**	**31**
Adjusted financial result	-52	-61		-126	-147	
Adjusted amortization and impairment losses on intangible assets	33	31		99	93	
Adjusted income before income taxes[a]	**178**	**359**	**102**	**729**	**940**	**29**
Adjusted income taxes	-46	-26		-156	-148	
Adjusted income after taxes[a]	**132**	**333**	**152**	**573**	**792**	**38**
thereof adjusted income attributable to non-controlling interests	4	3		10	8	
Adjusted net income[a]	**128**	**330**	**158**	**563**	**784**	**39**
Adjusted earnings per share in €[a]	**0.27**	**0.71**		**1.21**	**1.68**	

[a] Continuing operations.

Business performance in the first nine months of 2026

Sales increased by 4 percent to €11,144 million. The organic rise in sales of 7 percent resulted from higher volumes and prices but was held back by negative currency influences and other effects. The 14 percent improvement in **adjusted EBITDA** to €1,734 million was principally driven by higher selling prices. The adjusted EBITDA margin rose from 14.2 percent in the first nine months of 2025 to 15.6 percent.

The adjustments of -€609 million contained -€365 million for structural measures, especially the second phase of the Evonik Tailor Made program and the shutdown of the polyester business in the Custom Solutions segment. Further special items of -€242 million mainly comprised impairment losses on assets in the Custom Solutions, Infrastructure, and Advanced Technologies segments, reversals of impairment losses on assets in the Advanced Technologies segment, and expenses in connection with legal disputes. The prior-year adjustments of -€246 million mainly related to impairment losses on assets in the Infrastructure segment. The financial result declined from -€126 million to -€147 million as a result of lower interest income. Income before income taxes, continuing operations was 38 percent lower at €238 million. Income tax expense amounted to €74 million. Overall, net income decreased by €91 million to €156 million, principally due to higher expenses for structural measures.

After adjustment for special items, **adjusted net income** was 39 percent higher at €784 million, and adjusted earnings per share increased from €1.21 to €1.68.

1.2 Performance of the segments

Advanced Technologies

Key figures


	3rd quarter			1st nine months		
in € million	2025	**2026**	Change in %	2025	**2026**	Change in %
External sales	1,445	1,713	19	4,557	4,809	6
Adjusted EBITDA	202	377	87	759	950	25
Adjusted EBITDA margin in %	14.0	22.0	–	16.7	19.8	–
Adjusted EBIT	89	254	185	421	600	43
Capital expenditures[a]	72	66	-8	210	215	2
No. of employees as of September 30	–	–	–	9,189	9,364	2

[a] Capital expenditures for intangible assets, property, plant and equipment.

The Advanced Technologies segment has continued to benefit from its global position, especially since the outbreak of the war in the Middle East. Higher volumes and selling prices increased sales by 19 percent to €1,713 million in the **third quarter of 2026.**


The Animal Nutrition business benefited from higher volumes and improved prices for essential amino acids. Sales increased significantly. In the Organics business, crosslinkers continued to develop positively. Capacity utilization for high-performance polymers was ramped up further in response to improved demand. Overall, the Organics business registered a considerable rise in sales. Slightly higher sales were posted by the Inorganics business, which benefited from higher demand for precipitated silicas.

Sales Advanced Technologies



Adjusted EBITDA improved by 87 percent to €377 million, driven mainly by higher volumes and selling prices and the optimization programs. The adjusted EBITDA margin rose from 14.0 percent in the prior-year quarter to 22.0 percent.

Adjusted EBITDA Advanced Technologies



In the **first nine months of 2026,** sales in the Advanced Technologies segment grew by 6 percent to €4,809 million. This was attributable to higher volumes and prices but was held back by negative currency influences and other effects. The 25 percent increase in adjusted EBITDA to €950 million was mainly driven by volumes and prices. The adjusted EBITDA margin rose from 16.7 percent in the prior-year period to 19.8 percent.

Custom Solutions

Key figures


	3rd quarter			1st nine months		
in € million	2025	**2026**	Change in %	2025	**2026**	Change in %
External sales	1,340	1,394	4	4,133	4,151	–
Adjusted EBITDA	215	231	7	726	728	–
Adjusted EBITDA margin in %	16.0	16.6	–	17.6	17.5	–
Adjusted EBIT	140	155	11	501	498	-1
Capital expenditures[a]	72	84	17	200	221	11
No. of employees as of September 30	–	–	–	9,644	9,833	2

[a] Capital expenditures for intangible assets, property, plant and equipment.

Sales in the Custom Solutions segment rose 4 percent to €1,394 million in the **third quarter of 2026.** While volumes were unchanged, this was attributable to higher selling prices, mainly to pass on the increase in raw material costs. The rise in sales was held back by negative other effects.


The Additives business registered a positive demand trend for products for the paints and coatings industry and oil additives, resulting in higher selling prices. Sales of additives for polyurethane foams and consumer durables were around the prior-year level. Overall, sales rose considerably in the Additives business. In the Care business, sales were on par with the prior-year period.

Sales Custom Solutions



Adjusted EBITDA improved by 7 percent to €231 million. The adjusted EBITDA margin increased from 16.0 percent in the prior-year period to 16.6 percent.

Adjusted EBITDA Custom Solutions



In the **first nine months of 2026,** sales in the Custom Solutions segment were unchanged from the prior year at €4,151 million. Slightly higher volumes and selling prices were canceled out by negative currency effects. Adjusted EBITDA was also in line with the prior year at €728 million. The adjusted EBITDA margin slipped slightly from 17.6 percent to 17.5 percent.

Infrastructure

Key figures

	3rd quarter			1st nine months		
in € million	2025	**2026**	Change in %	2025	**2026**	Change in %
External sales	574	648	13	1,867	1,974	6
Adjusted EBITDA	54	80	48	154	228	48
Adjusted EBITDA margin in %	9.4	12.3	–	8.2	11.6	–
Adjusted EBIT	16	60	275	30	136	353
Capital expenditures[a]	21	20	-5	53	49	-8
No. of employees as of September 30	–	–	–	3,848	3,972	3

[a] Capital expenditures for intangible assets, property, plant and equipment.

Sales in the Infrastructure segment rose 13 percent to €648 million in the **third quarter of 2026.** This was attributable to the Oxeno business, where higher prices resulted in significant sales growth. Adjusted EBITDA improved by 48 percent to €80 million as Oxeno and SYNEQT posted higher earnings.

In the **first nine months of 2026,** sales grew 6 percent to €1,974 million. Adjusted EBITDA was 48 percent higher at €228 million.

2. Financial position

As a result of the improved operating performance, the cash flow from operating activities, continuing operations increased by €367 million to €1,198 million in the first nine months of 2026. The cash outflows for investments in intangible assets, property, plant and equipment increased by €50 million to €597 million. Overall, the **free cash flow** improved by €317 million to €601 million.

Cash flow statement (excerpt)

	1st nine months	
in € million	2025	**2026**
Cash flow from operating activities, continuing operations	831	1,198
Cash outflows for investments in intangible assets, property, plant and equipment	-547	-597
Free cash flow	**284**	**601**
Cash flow from other investing activities, continuing operations	61	46
Cash flow from financing activities, continuing operations	-328	-619
Change in cash and cash equivalents	**17**	**28**

The cash outflow for financing activities was €619 million and mainly resulted from the dividend payment for 2025 (€466 million). This was €79 million lower than in previous years due to the revision of the dividend policy at the beginning of 2026.

Net financial debt was €3,292 million, a decrease of €19 million compared with December 31, 2025. The increase resulting from the dividend payment was more than offset by the free cash flow of €601 million.

Net financial debt

in € million	Dec. 31, 2025	Sep. 30, 2026
Non-current financial liabilities[a]	-3,314	-2,767
Current financial liabilities[a]	-617	-1,189
Financial debt	**-3,931**	**-3,956**
Cash and cash equivalents	495	533
Current securities	124	122
Other financial investments	1	9
Financial assets	**620**	**664**
Net financial debt	**-3,311**	**-3,292**

[a] Excluding derivatives, excluding the liabilities for rebate and bonus agreements, and excluding customer credit liabilities.

Financial debt rose by €25 million to €3,956 million. In the second quarter, we drew down a €250 million tranche of the credit line provided by the European Investment Bank, which has a term of six years. In the third quarter, this was used to repay a Schuldschein loan of €92.5 million and commercial paper amounting to €50 million. The €500 million credit line agreed in 2024 has therefore been fully drawn.

Capital expenditures for intangible assets, property, plant and equipment amounted to €516 million in the first nine months of 2026 (9M 2025: €490 million). In principle, there is a slight timing difference in cash outflows for intangible assets, property, plant and equipment. Current major projects include the expansion of production capacities for SEPURAN® membranes in Austria and for precipitated silicas in North America.

3. Expected development

The global economy has been in a phase of heightened economic policy uncertainty for years. This has been exacerbated by the effects of the war in the Middle East, so **global economic conditions** will remain very challenging in the remainder of 2026. In an environment dominated by geopolitical tensions, elevated energy prices, restrictive monetary policy, rising interest rates, and sustained trade policy uncertainty, for the full year, we still assume weak global GDP growth of around 2.2 percent.

Further downside factors are structural challenges such as high global debt, the ongoing weakness of the domestic market in China, and the comparatively high energy costs in Europe. The global economy could also be impacted much more severely than to date by a financial or real estate crisis, the escalation of geopolitical conflicts, or a further rise in energy costs.

By contrast, growth impetus is coming from high investment in artificial intelligence, digitalization, energy infrastructure, and defense. Global economic growth is also supported by the continued robustness of the labor markets.

The European chemical industry benefited from special effects in the first half of the year, mainly due to the disruption of Asian competitors' supply chains and frontloading of inventories by customers. These effects weakened in the third quarter, and their significance seems likely to decline further in the remainder of the year.

The war in the Middle East has contributed to substantial price rises. Overall, we therefore assume that in 2026 raw material prices will be higher than in 2025.

Our forecast is based on the following assumptions:

- Global growth: 2.2 percent (unchanged from the beginning of the year)
- Internal raw material index above the prior-year level (unchanged since August 2026; beginning of 2026: slightly below the prior-year level)
- Average US dollar/euro exchange rate US$1.17 (unchanged since August 2026; previously: US$1.18; 2025: US$1.13)

Expected development of earnings

In the first nine months of 2026, Evonik's business performance was better than had been expected at the start of the year. Although there was still no broadly based macroeconomic recovery, the war in the Middle East brought a fundamental change in business development. While January and February were dominated by continued weak demand, in line with the original expectations, some of our businesses have observed both higher demand from customers and higher selling prices since the outbreak of the war at the beginning of March. In the Advanced Technologies segment, in particular, Evonik benefited from the supply bottlenecks affecting Asian competitors due to disruption of the supply of raw materials. Earnings were also supported by disciplined implementation of the efficiency enhancement measures. Based on this strong development, Evonik raised its outlook for adjusted EBITDA in mid-year.

For the remainder of this year, we assume that—alongside the usual seasonal effects—the weakening of the favorable economic conditions observed in the third quarter will continue. Moreover, although the market remains tight, there should be a continued slight normalization of prices in the Animal Nutrition business. Uncertainties remain, especially with regard to the availability of raw materials and the volatility of energy costs.

Having raised our earnings outlook in June, we are now giving more precise guidance. For the full year, we expect **adjusted EBITDA** to be in the upper half of the range of €2.0 billion to €2.2 billion (2025: €1,874 million). In 2026, the return on capital employed **(ROCE)** is expected to be considerably above the prior-year level (previously: slightly above the prior-year level; 2025: 6.1 percent).

Development of the segments

For most businesses in the **Advanced Technologies** segment, at the beginning of the year, we expected the ongoing phase of weak demand in our markets to continue in 2026. In the Animal Nutrition business, we assumed that essential amino acid prices would normalize.

However, since the outbreak of the war in the Middle East, this segment has benefited from positive developments in major businesses. In the Organics business, we are able to utilize the positive market momentum for crosslinkers resulting from less competitive pressure. In the wake of good demand, our high-performance polymers are benefiting from the continued ramp-up of our production capacities. In the third quarter, we noticed that supply from some Asian competitors was picking up again, but the increase was lower than we had initially expected. In the Animal Nutrition business, we have benefited from rising prices for essential amino acids so far this year, mainly due to the shortage of supply on the market, accompanied by continued solid, long-term volume growth. However, prices declined slightly in the third quarter, and we expect the price level to drop further up to year-end. Nevertheless, in view of the continued supply constraints, prices will probably not drop as fast as had been assumed in mid-year. Moreover, since the summer, we have been aided by the improved cost position in the USA resulting from completion of backward integration of our production there. A stable trend is expected for the Inorganics business, driven by its environment-friendly hydrogen peroxide specialties and aluminum oxide-based solutions for a wide range of end-markets.

Additionally, we will further improve our cost positions in the various businesses in this segment. Overall, we still anticipate that the earnings of the Advanced Technologies segment will be considerably higher than in the prior year (2025: €944 million).

In 2026, the Additives business in the **Custom Solutions** segment will continue to benefit from its specific customer solutions, which are geared to improving product properties and sustainability profiles. In particular, in the first half of the year, demand for applications for oil additives and in the coatings industry picked up from last year's low level, following a prolonged period of destocking. This upturn was partly due to frontloading in connection with the war in the Middle East. In some businesses, the third quarter was characterized by the usual seasonality of the summer months and normalization of orders on hand. Taking seasonal patterns into account, for the remainder of the year, we anticipate stable demand at the present level. A positive earnings contribution should come from additional volumes from the ramp-up of the new production plant in Singapore for alkoxides, which are used as catalysts for the production of biodiesel.

In the Care business, our system solutions for active cosmetic ingredients should continue their profitable growth. New areas of application and sustained healthy demand for our innovative rhamnolipids (biosurfactants) will lead to rising utilization of the production facility in Slovakia, which was completed in 2024. However, these positive developments will be largely neutralized by volume losses on basic products, which are suffering from increased competitive pressure. Looking at the products for the pharmaceuticals sector, the stronger focus on lipids—accompanied by the closure and divestment of the production assets for keto and amino acids—will result in efficiency gains.

Overall, we still anticipate that earnings in the Custom Solutions segment will be around the prior-year level (2025: €909 million).

We anticipate that the **Infrastructure** segment will develop favorably. The services at the German sites in Marl and Wesseling, which have been operated by our new company SYNEQT GmbH since January 1, 2026, will benefit from the new setup and the savings measures that have been initiated. In addition, the improvement in prices and margins in the Oxeno business (C_4 chemicals) from the low 2025 level may be stronger than originally expected. For this segment, together with Others, we still expect earnings to be significantly above the prior-year level in 2026 (2025: €21 million).

Financing and investments

In recent years, **cash outflows for investments in intangible assets, property, plant and equipment** have been characterized by restraint. Due to the declining earnings development in 2025, we reduced cash outflows for investments to €750 million, which was below the long-term average. We will continue our disciplined approach in 2026 and maintain cash outflows at this level (2025: €748 million).

Owing to strict discipline in capital expenditures and net working capital, Evonik was able to generate a high absolute **free cash flow** and thus an attractive cash conversion rate in 2025, even in a challenging environment. We will continue this in 2026. We still expect the cash conversion rate to be around our target of 40 percent this year (2025: 37 percent; absolute free cash flow: €695 million).

Forecast for 2026

Forecast performance indicators	2025	Forecast for 2026[a]	Revised forecast for 2026 as of June[b]	Current forecast for 2026
Adjusted EBITDA	€1.9 billion	Between €1.7 billion and €2.0 billion	Between €2.0 billion and €2.2 billion	In the upper half of the range of €2.0 billion to €2.2 billion
ROCE	6.1%	At the prior-year level	Slightly above the prior-year level	Considerably above the prior-year level
Cash outflows for investments in intangible assets, property, plant and equipment	€748 million	Around €750 million	Around €750 million	Around €750 million
Free cash flow: cash conversion rate[c]	37%	Around 40%	Around 40%	Around 40%

[a] As reported in the Financial and Sustainability Report 2025.
[b] As reported on June 26, 2026.
[c] Ratio of free cash flow to adjusted EBITDA.

Selected financial information as of September 30, 2026

Income statement

	3rd quarter		1st nine months	
in € million	2025	**2026**	2025	**2026**
Sales	3,391	3,825	10,666	11,144
Cost of sales	-2,775	-2,965	-8,111	-8,458
Gross profit on sales	**616**	**860**	**2,555**	**2,686**
Selling expenses	-420	-497	-1,308	-1,376
Research and development expenses	-104	-119	-315	-309
General administrative expenses	-111	-253	-362	-497
Other operating income	54	37	180	103
Other operating expense	-61	-36	-245	-227
Result from investments recognized at equity	1	2	5	5
Income before financial result and income taxes, continuing operations (EBIT)	**-25**	**-6**	**510**	**385**
Interest income	7	16	42	37
Interest expense	-56	-69	-164	-176
Other financial income/expense	-3	-8	-4	-8
Financial result	**-52**	**-61**	**-126**	**-147**
Income before income taxes, continuing operations	**-77**	**-67**	**384**	**238**
Income taxes	-25	17	-127	-74
Income after taxes, continuing operations	**-102**	**-50**	**257**	**164**
Income after taxes, discontinued operations	–	–	–	–
Income after taxes	**-102**	**-50**	**257**	**164**
thereof attributable to non-controlling interests	4	3	10	8
thereof attributable to shareholders of Evonik Industries AG (net income)	-106	-53	247	156
Earnings per share in € (basic and diluted)	**-0.23**	**-0.11**	**0.53**	**0.33**
thereof continuing operations	-0.23	-0.11	0.53	0.33
thereof discontinued operations	–	–	–	–

Balance sheet

in € million	Dec. 31, 2025	Sep. 30, 2026
Goodwill	4,411	4,492
Other intangible assets	686	598
Property, plant and equipment	6,006	5,993
Right-of-use assets	892	775
Investments recognized at equity	45	44
Trade accounts receivable	1	1
Other financial assets	419	384
Deferred taxes	436	502
Other income tax assets	22	64
Other non-financial assets	96	69
Non-current assets	**13,014**	**12,922**
Inventories	2,300	2,792
Trade accounts receivable	1,525	1,864
Other financial assets	220	229
Other income tax assets	94	66
Other non-financial assets	333	406
Cash and cash equivalents	495	533
Current assets	**4,967**	**5,890**
Total assets	**17,981**	**18,812**

in € million	Dec. 31, 2025	Sep. 30, 2026
Issued capital	466	466
Capital reserve	1,168	1,168
Retained earnings	7,173	6,926
Other equity components	-697	-535
Equity attributable to shareholders of Evonik Industries AG	**8,110**	**8,025**
Equity attributable to non-controlling interests	64	65
Equity	**8,174**	**8,090**
Provisions for pensions and other post-employment benefits	1,490	1,390
Other provisions	591	758
Other financial liabilities	3,476	2,936
Deferred taxes	576	616
Other income tax liabilities	228	258
Other non-financial liabilities	118	123
Non-current liabilities	**6,479**	**6,081**
Other provisions	787	1,017
Trade accounts payable	1,401	1,632
Other financial liabilities	689	1,408
Other income tax liabilities	58	76
Other non-financial liabilities	393	508
Current liabilities	**3,328**	**4,641**
Total equity and liabilities	**17,981**	**18,812**

Cash flow statement

in € million	3rd quarter 2025	3rd quarter **2026**	1st nine months 2025	1st nine months **2026**
Income before financial result and income taxes, continuing operations (EBIT)	-25	-6	510	385
Depreciation, amortization, impairment losses/reversal of impairment losses on non-current assets	428	317	928	933
Result from investments recognized at equity	–	-2	-5	-5
Gains/losses on the disposal of non-current assets	5	5	24	10
Change in inventories	94	-101	-39	-440
Change in trade accounts receivable	52	30	-107	-303
Change in trade accounts payable	-67	-98	-110	294
Change in provisions for pensions and other post-employment benefits	-28	-6	-45	-31
Change in other provisions	40	394	-264	358
Change in miscellaneous assets/liabilities	7	60	-15	67
Cash inflows from dividends	–	–	19	18
Cash outflows for income taxes	-43	-47	-152	-129
Cash inflows from income taxes	18	16	87	41
Cash flow from operating activities, continuing operations	**481**	**562**	**831**	**1,198**
Cash outflows for investments in intangible assets, property, plant and equipment	-181	-193	-547	-597
Cash outflows relating to the loss of control over businesses	-1	-1	-2	-2
Cash inflows from divestments of intangible assets, property, plant and equipment	1	2	9	18
Cash inflows relating to the loss of control over businesses	–	–	9	–
Cash inflows from divestment of other shareholdings	–	–	3	5
Cash inflows/outflows relating to securities, deposits, and loans	164	-7	12	-5
Cash inflows from interest	3	4	30	12

in € million	3rd quarter 2025	3rd quarter **2026**	1st nine months 2025	1st nine months **2026**
Government grants received for assets	–	8	–	18
Cash flow from investing activities, continuing operations	**-14**	**-187**	**-486**	**-551**
Capital inflows from non-controlling interests	–	–	4	–
Cash outflows for dividends to shareholders of Evonik Industries AG	–	–	-545	-466
Cash outflows for dividends to non-controlling interests	-4	-4	-9	-9
Cash outflows due to changes in ownership interests in subsidiaries	–	–	-19	–
Cash outflows for the purchase of treasury shares	–	–	-1	–
Cash inflows from the sale of treasury shares	–	–	1	–
Cash inflows from the addition of financial liabilities	921	17	1,736	420
Cash outflows for repayment of financial liabilities	-1,252	-203	-1,424	-485
Cash inflows/outflows in connection with financial transactions	–	–	5	21
Cash inflows from interest on interest rate hedges	3	–	3	5
Cash outflows for interest	-53	-47	-79	-105
Cash flow from financing activities, continuing operations	**-385**	**-237**	**-328**	**-619**
Change in cash and cash equivalents	**82**	**138**	**17**	**28**
Cash and cash equivalents as of July 1/January 1	**379**	**390**	**461**	**495**
Change in cash and cash equivalents	82	138	17	28
Changes in exchange rates and other changes in cash and cash equivalents	-7	5	-24	10
Cash and cash equivalents as on the balance sheet as of September 30	**454**	**533**	**454**	**533**

Segment report

Segment report by operating segments—3rd quarter

	Advanced Technologies		Custom Solutions		Infrastructure		Enabling functions, other activities, consolidation		**Total Group (continuing operations)**	
in € million	2025	**2026**	2025	**2026**	2025	**2026**	2025	**2026**	2025	**2026**
External sales	1,445	1,713	1,340	1,394	574	648	32	70	3,391	3,825
Internal sales	21	20	27	11	99	179	-147	-210	–	–
Total sales	1,466	1,733	1,367	1,405	673	827	-115	-140	3,391	3,825
Cost of sales	-1,118	-1,068	-1,007	-1,186	-783	-720	133	9	-2,775	-2,965
Adjusted EBITDA	202	377	215	231	54	80	-23	-59	448	629
Adjusted EBITDA margin in %	14.0	22.0	16.0	16.6	9.4	12.3	–	–	13.2	16.4
Adjusted EBIT	89	254	140	155	16	60	-48	-80	197	389
Capital expenditures[a]	72	66	72	84	21	20	8	12	173	182
Financial investments	–	–	–	–	–	–	2	1	2	1

[a] For intangible assets, property, plant and equipment.

Segment report by regions—3rd quarter

	Europe, Middle East & Africa		Americas		Asia-Pacific		**Total Group (continuing operations)**	
in € million	2025	**2026**	2025	**2026**	2025	**2026**	2025	**2026**
External sales[a]	1,609	1,792	1,016	1,182	766	851	3,391	3,825
Capital expenditures	97	117	58	51	18	14	173	182

[a] External sales Europe, Middle East & Africa: thereof Germany €652 million (Q3 2025: €609 million).

Segment report by operating segments—1st nine months

	Advanced Technologies		Custom Solutions		Infrastructure		Enabling functions, other activities, consolidation		**Total Group (continuing operations)**	
in € million	2025	**2026**	2025	**2026**	2025	**2026**	2025	**2026**	2025	**2026**
External sales	4,557	4,809	4,133	4,151	1,867	1,974	109	210	10,666	11,144
Internal sales	70	64	85	33	357	507	-512	-604	–	–
Total sales	4,627	4,873	4,218	4,184	2,224	2,481	-403	-394	10,666	11,144
Cost of sales	-3,390	-3,306	-2,950	-3,148	-2,220	-2,289	449	285	-8,111	-8,458
Adjusted EBITDA	759	950	726	728	154	228	-122	-172	1,517	1,734
Adjusted EBITDA margin in %	16.7	19.8	17.6	17.5	8.2	11.6	–	–	14.2	15.6
Adjusted EBIT	421	600	501	498	30	136	-196	-240	756	994
Capital expenditures[a]	210	215	200	221	53	49	27	31	490	516
Financial investments	–	–	–	–	–	–	4	4	4	4
No. of employees as of September 30	9,189	9,364	9,644	9,833	3,848	3,972	8,616	7,150	31,297	30,319

[a] For intangible assets, property, plant and equipment.

Segment report by regions—1st nine months

	Europe, Middle East & Africa		Americas		Asia-Pacific		**Total Group (continuing operations)**	
in € million	2025	**2026**	2025	**2026**	2025	**2026**	2025	**2026**
External sales[a]	5,118	5,290	3,131	3,308	2,417	2,546	10,666	11,144
Non-current assets in accordance with IFRS 8 as of September 30	6,564	6,235	4,057	4,165	1,469	1,570	12,090	11,970
Capital expenditures	259	299	173	180	58	37	490	516
No. of employees as of September 30	20,777	19,979	5,544	5,517	4,976	4,823	31,297	30,319

[a] External sales Europe, Middle East & Africa: thereof Germany €1,915 million (9M 2025: €1,981 million).

Financial calendar

Financial calendar 2027

Event	Date
Report on Q4 2026 and FY 2026	March 4, 2027
Interim report Q1 2027	May 4, 2027
Annual shareholders' meeting 2027	June 3, 2027
Interim report Q2 2027	August 4, 2027
Interim report Q3 2027	November 4, 2027

Credits

Published by
Evonik Industries AG
Opernplatz 1
45128 Essen, Germany
www.evonik.com

Contact
Communications
Phone +49 201 177-3315
presse@evonik.com

Investor Relations
investor-relations@evonik.com

The English version of this quarterly statement is a translation of the German original report and is provided for information only.